Clinical Trials

65 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT04824092 2026-04-01

frontMIND

899 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT01190930 2026-03-31

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

9,350 enrolled 51 charts

Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04529772 2026-03-31

ESCALADE

611 enrolled

Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05761171 2026-03-31

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

78 enrolled

Phase 2/3 Active not recruiting

Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02405676 2026-03-19

BNHL-2015

200 enrolled

Lymphoma

NCT02845882 2026-03-18

LBL-2016 for Children or Adolescents in China

150 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02166463 2026-03-17

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

600 enrolled 14 charts 1 FDA

Ann Arbor Stage IIB Hodgkin Lymphoma

NCT03007147 2026-02-23

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

475 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03755804 2026-02-23

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

232 enrolled

Hodgkin Disease, Neoplasms

NCT03407144 2026-02-19

MK-3475-667

340 enrolled

Hodgkin Disease

NCT03147612 2026-02-17

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

22 enrolled

Blast Crisis, Leukemia, Myeloid, Accelerated Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04980222 2026-02-17

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

46 enrolled

Lymphoma

NCT06356129 2026-02-12

GOLSEEK-1

850 enrolled

Lymphoma

NCT03710772 2026-02-11

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

51 enrolled

Lymphoma, Mantle-Cell

NCT03274492 2026-02-06

POLARIX

1,000 enrolled 2 FDA

Lymphoma, Large B-Cell, Diffuse

NCT03749018 2026-02-06

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

30 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06097364 2026-02-06

OLYMPIA-2

733 enrolled

Lymphoma, Follicular, Recurrence

NCT06091865 2026-02-05

OLYMPIA-3

904 enrolled

Phase 1 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04323956 2026-02-02

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

50 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03943901 2026-01-29

Split-Dose R-CHOP for Older Adults With DLBCL

27 enrolled 11 charts

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT03020030 2026-01-22

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

560 enrolled

Phase 1/2 Active not recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03808610 2026-01-09

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

50 enrolled

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06425302 2026-01-08

GOLSEEK-2

90 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Lymphoma, Follicular

NCT02553460 2025-12-10

Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I

50 enrolled 12 charts

Phase 2/3 Active not recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03117751 2025-12-05

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

790 enrolled

Phase 1/2 Active not recruiting

Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02223208 2025-12-02

FIL_PTCL13

89 enrolled

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral

NCT02101853 2025-12-01

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

669 enrolled 14 charts

Burkitt Lymphoma

NCT02112916 2025-12-01

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

847 enrolled 19 charts

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02003222 2025-11-28

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

488 enrolled 13 charts 2 FDA

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02883049 2025-11-26

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

5,949 enrolled 28 charts

Burkitt Lymphoma

NCT03589326 2025-11-26

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

245 enrolled 15 charts 2 FDA

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

NCT02427620 2025-11-21

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

131 enrolled

Lymphoma, Mantle-Cell

NCT05371093 2025-10-15

ZUMA-22

231 enrolled

Phase 1 Active not recruiting

Lymphoma, Follicular

NCT05270057 2025-10-09

LONCA

11 enrolled